Initial Data Reported from Clinical Study Evaluating ME-344 + Avastin in Relapsed Metastatic CRC Patients April 16, 2024
Positive Preliminary PFS and Long-term ctDNA Data from Ph 2 Portion of Ongoing Ph 2/3 Study of Personalized Cancer Vaccine, GRANITE, in 1L Metastatic MSS-CRC announced April 8, 2024
Positive Interim Data Announced from Randomized Ph 2 Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer April 8, 2024
Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced April 8, 2024
Zanidatamab BLA for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer initiated April 8, 2024
First Participant dosed in Ph 3 Study (Neoshot) of IBI310 + Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy April 2, 2024
Positive Findings announced from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research March 26, 2024
CheckMate -9DW Trial of Opdivo + Yervoy Meets Primary Endpoint of OS for the 1L Treatment of Advanced HCC March 26, 2024
PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA March 26, 2024
Global Ph 3 Clinical Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by EMA March 19, 2024
FDA clears INDs for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b March 19, 2024
FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 19, 2024
New clinical data from 2L ONSEMBLE trial provides further evidence of the efficacy of onvansertib + FOLFIRI/bev in bev naïve RAS-mutated mCRC patients March 12, 2024
Global Ph 3 Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib Granted by EMA March 12, 2024
DURIPANC Ph 1b/2 clinical trial of Ampligen with Imfinzi for the treatment of pancreatic cancer opened for enrollment and enrolled first subject March 4, 2024
BLA for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA March 4, 2024
Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA February 26, 2024
